RxDoctor Payments Data

Linda Crawford, DO

Internal Medicine · Sierra Madre, CANPI 1841360427

Payments from drug & device makers

$401in general payments, 2019–2025

Across 13 payments — averaging $30.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$140
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$57
  • Amarin Pharma, Inc.$49
  • Teva Pharmaceuticals USA, Inc.$45
  • AbbVie$44
  • Coloplast$28
  • plus $38 from 2 others

What the payments were for

  • Food & beverage$401100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$401 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$20,532
Medicare patients
76
Services billed
237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate39$44,695
EliquisApixaban31$30,427
OzempicSemaglutide30$26,679
NuedextaDextromethorphan Hbr/Quinidine13$20,073
JardianceEmpagliflozin14$8,301
Benicar HctOlmesartan/Hydrochlorothiazide12$5,021
Ramelteon21$3,662
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,991
ValacyclovirValacyclovir Hcl61$2,674
Atorvastatin Calcium230$2,351
Lidocaine16$2,307
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen113$2,210
Rosuvastatin Calcium126$1,913
Levothyroxine Sodium191$1,655
Albuterol Sulfate HfaAlbuterol Sulfate48$1,550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$30,42731 claims
AbbVieSynthroid$44$96116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Sierra Madre

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →